Johnson & Johnson leans into multiple myeloma momentum in Europe, as a talc-related verdict risk recedes

Johnson & Johnson said it has received positive regulatory developments in Europe related to its multiple myeloma therapy Tecvayli, according to a market report published July 1. The update centers on Tecvayli when used in combination with Darzalex SC, a subcutaneous (under-the-skin) formulation of daratumumab.

The same report attributes the regulatory progress to phase III clinical trial data, pointing to late-stage evidence as the basis for the European regulatory pathway. Phase III trials are the final, large-scale studies typically used to support approval for new uses of a drug or new drug combinations.

Tecvayli is positioned in J&J’s oncology portfolio as a therapy aimed at treating patients with multiple myeloma, a cancer that affects plasma cells in the bone marrow. Darzalex SC provides an administration option designed to be less invasive than infusions, which can be a practical consideration for treatment schedules in routine care.

Separately, the report frames the update as arriving alongside shifting sentiment around a talc-related verdict. The headline characterizes the verdict as easing one risk for the company, suggesting that legal uncertainty has been a recurring factor influencing how investors weigh J&J’s outlook.

While the report indicates that the talc issue is less acute than before, it does not spell out the specific jurisdiction, the magnitude of potential liability, or whether J&J can still face appeals or additional litigation outcomes. Johnson & Johnson also did not disclose further details in the market post beyond the general “one risk” framing.

From a business perspective, the European regulatory update matters because J&J’s ability to expand approvals for established oncology regimens can help sustain demand as its drug mix evolves. For oncology-focused medicines, approvals tied to phase III data can unlock broader prescribing use cases, including new combinations and treatment settings.

The company’s broader sector context is a healthcare market where investors often try to balance two variables: the pace of new clinical approvals in areas like oncology and the weight of regulatory, safety, and litigation developments. In that framework, a regulatory catalyst can improve expectations for future revenue durability, even as legal headlines can keep risk premiums elevated.